A Study to Evaluate the Safety and Efficacy of Obinutuzumab Compared With Placebo in Participants With Lupus Nephritis (LN)

NCT02550652 PHASE2 COMPLETED Results posted

This Phase II study will compare the efficacy and safety of obinutuzumab plus mycophenolate mofetil (MMF)/mycophenolic acid (MPA) with placebo plus MMF/MPA in participants with proliferative LN.

Details

Lead sponsor	Hoffmann-La Roche
Phase	PHASE2
Status	COMPLETED
Enrolment	126
Start date	Fri Nov 13 2015 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Wed Aug 02 2023 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Lupus Nephritis

Interventions

• Mycophenolate Mofetil/Mycophenolic Acid
• Obinutuzumab
• Placebo
• Methylprednisolone
• Prednisone

Countries

France, Colombia, Costa Rica, Italy, Panama, Peru, Israel, Mexico, Argentina, Spain, United States, Brazil